ICON Public Limited Company
Financials
Valuation Metrics
ICON Public Limited Company's Market Cap is $13.20B. At end of 2025 it was $14.10B. Ranked #774 of 3,121 in US market (top 25%), #242 of 1,463 on NASDAQ (top 17%), #49 of 205 in Health Care Equipment & Services (top 24%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $13.20B | US#774/3,121 Sec#49/205 |
| Revenue | $8.25B | US#643/3,121 Sec#38/205 |
| Net Income | $329M | US#1,050/3,121 Sec#54/205 |
| Total Assets | $16.40B | US#708/3,121 Sec#33/205 |
| Net Assets | $9.38B | US#448/3,121 Sec#24/205 |
| Employees | 40,200 | US#307/3,121 Sec#30/205 |
| Value | ||
| P/E | 40.13x | US#1,805/3,121 Sec#83/205 |
| P/B | 1.41x | US#791/3,121 Sec#40/205 |
| P/S | 1.60x | US#1,086/3,121 Sec#74/205 |
| EV/EBITDA | 12.66x | US#1,238/3,121 Sec#41/205 |
| FCF Yield | 10.20% | US#567/3,121 Sec#24/205 |
| Profitability | ||
| ROE | 3.51% | US#1,925/3,121 Sec#97/205 |
| ROA | 2.01% | US#1,641/3,121 Sec#101/205 |
| Op. Margin | 10.15% | US#1,586/3,121 Sec#76/205 |
| Revenue Growth | 2.01% | US#2,085/3,121 Sec#156/205 |
| Earnings Growth | -58.59% | US#1,770/3,121 Sec#92/205 |
| Financial Health | ||
| Debt Ratio | 74.88% | US#832/3,121 Sec#84/205 |
| Total Debt | $3.49B | US#875/3,121 Sec#40/205 |
| FCF | $1.35B | US#483/3,121 Sec#32/205 |
| Cash | $928M | US#728/3,121 Sec#40/205 |
| Current Ratio | 0.95x | US#2,336/3,121 Sec#190/205 |
| Net Debt/EBITDA | 2.06x | US#1,336/3,121 Sec#82/205 |
| Performance | ||
| 1Y Return | -3.16% | US#1,921/3,121 Sec#133/205 |
| 1M Return | 1.57% | US#768/3,121 Sec#83/205 |
| From 52W High | -16.79% | US#1,271/3,121 Sec#90/205 |
| 1Y MDD | -60.54% | US#2,789/3,121 Sec#173/205 |
| Trading | ||
| Volume | 1,152,317 shares | US#1,277/3,121 Sec#77/205 |
| Trading Value | $198M | US#456/3,121 Sec#38/205 |
| Per Share | ||
| EPS | $4.23 | US#811/3,121 Sec#43/205 |
| BPS | $120.59 | US#75/3,121 Sec#8/205 |
Company Info
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.